Lifeforce Membership vs Marek Health Guided Optimization (pay-per-service)
Specs, prices, editor verdict, and who should buy which - compared side-by-side.
Lifeforce Lifeforce Membership (ultra premium, $149–$599/mo) vs Marek Health Guided Optimization (pay-per-service) (premium, $250–$2,000/test) - different tools for different jobs (see the per-product details below).
Compared on 0 shared specs · cross-category comparison (ai software vs diagnostic).
These are close picks. Both score in the same range. The right call depends on buyer profile - read the per-buyer recommendations below.
Who should buy which
Buyers who want a single concierge longevity provider - labs, coaching, prescriptions - and have the budget for $300-800/mo all-in.
You're data-first and don't need coaching (Function is half the cost), or you already have a longevity clinician.
Experienced TRT/HRT users running multi-medication protocols, biomarker-literate buyers who want clinically aggressive guidance, and the intersection of "performance optimization" and "wants real bloodwork supervision."
You're TRT-curious for the first time (start with Hone), you can't budget $300+/mo all-in, or you want a higher-touch in-clinic experience (Defy Medical or Cenegenics).
Go deeper
Frequently asked
Which is better, the Lifeforce Membership or the Marek Health Guided Optimization (pay-per-service)?
They are closely matched on our scoring, so the right pick comes down to your priorities. The verdict and spec table above compare them on price, features, and who each one suits.
How much do they cost?
Lifeforce Membership: $149 to $599. Marek Health Guided Optimization (pay-per-service): $250 to $2,000. Prices are verified against the manufacturer; check the live links for current pricing.
Who should buy which one?
Lifeforce Membership: Buyers who want a single concierge longevity provider - labs, coaching, prescriptions - and have the budget for $300-800/mo all-in. Marek Health Guided Optimization (pay-per-service): Experienced TRT/HRT users running multi-medication protocols, biomarker-literate buyers who want clinically aggressive guidance, and the intersection of "performance optimization" and "wants real bloodwork supervision."